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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
botulinum toxin injections improve the freezing of gait (FOG) episodes experienced by patients 
diagnosed with Parkinson’s disease (PD). 
 
STUDY DESIGN: This review is based on three randomized controlled trials published in 2004, 
2005, and 2007. All of the studies compared the efficacy as well as safety of using botulin toxin 
injections to treat FOG episodes experienced by PD patients. 
 
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and 
were found using PubMed searches.  
 
OUTCOMES MEASURED: For all studies, the safety and efficacy of botulin toxin injections 
in the legs of patients with PD who experience FOG episodes was evaluated using clinical 
assessment as well as questionnaires such as the United Parkinson’s Disease Rating Scale 
(UPDRS). The post-treatment measurements were compared to pre-treatment baseline 
assessments to determine any improvements. 
 
RESULTS: Leg weakness, skin changes, and increase in number of falls were a few adverse 
reactions that occurred after treatment with botulinum toxin injections. The three studies 
completed by Wieler, Fernandez, and Gurevich had statistically insignificant results.  
 
CONCLUSION: All three of the RCTs that were evaluated did not demonstrate a statistically 
significant difference after the patients received botulinum toxin injections. Botulinum toxin 
injections are not proven to be effective in the treatment of PD FOG episodes. However, as there 
were no life threatening or extremely unsafe adverse reactions, further future studies would be 
warranted in which a larger sample size could be evaluated.  
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INTRODUCTION 
 Parkinson’s disease (PD) is a degenerative, chronic and progressive disease that 
specifically targets and affects the dopaminergic cells of the substantia nigra causing cognitive 
and movement disorders.1 The disease is fairly variable from patient to patient.1 Cognitive 
impairments range from dementia to mood and sleep dysfunctions to psychosis.1 Although 
cognitive dysfunction can be debilitating, this paper focuses on the physical movement disorders 
experienced by PD patients, including bradykinesia, balance disorders, rigidity, tremors, and 
freezing of gait (FOG) episodes.2  It is important to note that PD is not a fatal disease in and of 
itself, but morbidity is related to PD-related complications including falls, pneumonia, or 
choking.1 
 Parkinson’s disease is the second most common neurodegenerative disease generally 
diagnosed in patients around 60 years old.3 It is a growing disease in the United States as the 
population continues to age.4 Currently, PD affects 1 million patients in the United States and 
about 7 to 10 million people worldwide.4 It is projected that this number will nearly double by 
the year 2030.4 An estimated 60,000 Americans are diagnosed each year.4 
 The economic burden associated with PD is expected to increase as the number of 
patients diagnosed with this disease continues to climb.3 In the year 2010, it was estimated that 
the direct costs of PD was around $14.4 billion.3 Medication costs alone for a single individual 
battling PD averages to about $2,500 a year and therapeutic surgery is approximately $100,000 
per patient.3 When indirect costs associated with PD, such as lost income due to illness and 
social security payments are added to the direct costs, it is projected that $25 billion per year is 
spent just in the United States alone.3 Although an exact number of health care visits per year due 
to PD is unknown, patients with PD experience worsening symptoms as their disease progresses, 
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leading to higher direct costs due to an increase in medications, hospitalizations, office visits, 
and need for nursing home care.3 Fifteen percent of PD patients are found in nursing homes, 
which accounts for about 60% of the direct costs accumulated.3 
 The exact cause of PD is unknown, however, it is thought to be a combination of family 
history, genetics, and environmental causes. One of the most important risk factors associated 
with PD is aging.2 Fifteen percent of patients diagnosed with PD have a family member with PD 
as well.2 It has been found that when PD occurs at an early age it is often associated with a gene 
mutation such as parkin, PINK1, LRRK2, DJ-1, and glucocerebrosidase.2 
As stated earlier, the presentation and disease progression can vary greatly from patient to 
patient. The most common presenting symptom is an intermittent resting tremor.2 Parkinson’s 
disease classically presents with one-sided symptoms that begin to progress over the years and 
spread to include symptoms affecting the other side of the body as well.2 PD may be detected by 
the decreased ability to perform repetitive movements.2 Another key feature, bradykinesia, is the 
reason for the stooped, shuffled gait characteristic of a PD patient.2 Rigidity is commonly seen in 
PD which causes stiffness and decreased flexibility. Secondary to these motor dysfunctions, 
patients may experience freezing of gait (FOG). Patients describe FOG as feeling as if their feet 
are glued to the floor.2 This sensation is most commonly experienced when patients attempt to 
take a first step while walking.2 This sensation greatly increases a patient’s risk for falling.2 
Other key features of the disease are micrographia, mask-like expressions, unwanted 
accelerations of speech and gait, loss of smell, mood disorder, memory difficulties, and 
orthostatic hypotension.2  
Parkinson’s disease is generally treated symptomatically, as there is no cure. The hope is 
that by controlling the symptoms, disease progression can be slowed and complications due to 
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PD can be prevented. The decision to begin treatment is generally made when the symptoms are 
negatively affecting ability to perform activities of daily living and quality of life.2  
There are six classes of drugs used to treat PD. The most effective and commonly used 
medication is Levodopa, which is usually given as a combination pill of Carbidopa and 
Levodopa called Sinemet.2 The biggest concern with Levodopa is that over time, motor-
fluctuations begin to occur including “wearing off” effect. The “wearing off” effect is when the 
medication begins to wear off before the next scheduled dose.2 Monoamine oxidase inhibitors 
are another group of medications for PD that work to inactivate the breakdown of dopamine.2 
These work to decrease the symptoms of PD by allowing dopamine to remain in the brain for a 
longer period of time.2 Other medications include dopamine agonists, Catechol-O-methyl 
transferase (COMT) inhibitors, and Amantadine.2 Management of common conditions found in 
PD patients such as depression, sleep disorders, dementia, psychosis and hallucinations are all 
treated separately and individualized to each patient.2 
 Currently, there is not a cure for PD and all the above treatments are aimed toward 
slowing down the disease progression, improving symptoms, and preserving the ability to 
perform activities of daily living.2 The method of treatment being proposed is whether or not 
BTX being injected into the leg muscles of patients with PD may be used to further control the 
number and severity of the FOG episodes in hopes that patients would experience less falls, less 
injury, and retain more independence. The use of botulinum toxin (BTX), a gram-positive 
anaerobe, is currently not a suggested or utilized treatment for PD.5 
OBJECTIVE 
 The objective of this selective evidence based medicine review is to determine whether or 
not BTX injections improve the episodes of FOG in PD patients. 
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METHODS 
 Three studies were assessed: a double blind randomized, placebo-controlled pilot study5, 
a two period cross over design RCT7, and a double blind randomized, placebo controlled, 
parallel-group study8. The intervention being used in all three RCTs was BTX injections into the 
gastrocnemius and soleus muscles of the leg while the comparison group received placebo 
injections of saline into the gastrocnemius and soleus muscle complex. The studies selected were 
determining whether or not there was a decrease in the FOG episodes experienced by PD 
patients after BTX injections.  
Data was collected using a detailed search of Cochrane Systematic review as well as 
PubMed from the years 2004 to present. “Parkinson’s disease,” “freezing of gait,” and 
“botulinum toxin injections” were keywords that were used in this search.  Articles were selected 
based on their relevance to clinical practice and importance to patient-oriented outcomes.  All 
articles chosen for this review were peer-reviewed and published in well-known journals.   
Inclusion criteria for all three RCTs selected for review consisted of RCTs that were peer 
reviewed and published within the past fifteen years. The studies needed to include PD patients 
with FOG as a major complaint, that were severe enough to need treatment. Similarly, studies 
were excluded if they not published in the past 15 years. Studies were also omitted if they did not 
use UPDRS to measure outcomes.  
The three RCTs selected, all reported statistics using mean change from baseline as well 
as p-values. In the Wieler et al. study, independent T-Tests were used to examine differences 
between groups and assess for carryover.6 Paired T-tests were performed to look for pooled 
group effects without regard to order of treatment.6 In the Fernandez et al. study, all analyses 
were performed using the SAS statistical software.7 Finally, in the Gurevich et al. study, they 
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used mixed effects models for repeated measures to investigate changes over time in the 
subject’s motor status to handle an unbalanced design where subjects have different number of 
repeated measures.8 
Table 1 : Demographics and Characteristics of included studies 
Study Type # 
Pati
ents 
Age (yrs) Inclusion criteria Exclusion 
Criteria 
W/
D 
Interventions 
Wieler 
(2005)6 
RCT-  
Double 
blind  
cross-
over 
design 
12 Mean age 
of 77 
years 
 
(range 53 
-79 years)  
-Diagnosis of PD with FOG as a 
major complaint 
-Good locomotion between freezing 
episodes 
-Optimal, stable medical treatment 
for PD 
-Ability to keep accurate diaries and 
attend scheduled visits 
If unable 
to keep a 
daily diary  
0 200-300 U of BTX-
A injections into 
the medial and 
lateral heads of the 
gastrocnemius and 
soleus for a total of 
six injections. 
 
Fernan
dez 
(2004)7 
RCT-  
Double 
Blind, 
Placebo 
Parallel-
design 
14 Mean age 
of 74 
years 
(range 61–
87 years)  
-Presence of 3-4 cardinal features of 
resting tremor, rigidity, 
bradykinesia, and postural 
instability, with a significant 
sustained response to anti-PD 
therapy 
-A Hoehn and Yahr stage of 3  
-Stable PD medication for at least 
30 days 
-FOG severe enough to need 
treatment 
-Optimized on their present anti-PD 
therapy 
 
None 0 BTX- type B 5,000 
U or placebo was 
injected into 4 
areas of the soleus-
gastrocnemius 
complex of the 
predominantly 
affected leg. 
 
Gurevi
ch 
(2007)8 
RCT-  
Double 
blind 
placebo-
design  
11 Mean age 
was 69.4 
 
(Range 56 
– 86 
years)  
-PD patients during the “off” state 
for at least 3 months. 
-Diagnosed by 2 independent 
movement disorders specialist 
-Disabling FOG 
-Scored at least a 14 in the FOG 
questionnaire 
-FOG episodes with duration of 3 
seconds and more every day 
affecting their ability to walk and 
their ADLs. 
-If unable 
to walk 
independe
ntly 
-If had 
been 
exposed to 
BTX-A in 
the past. 
0 BTX 150 IU was 
injected into both 
legs (50 IU into 
medial and lateral 
heads of the 
gastrocnemius and 
50 IU into the 
soleus of each leg 
for a total of 300 
IU per patient). 
 
OUTCOMES MEASURED 
 All outcomes measured for this study were patient oriented outcomes (POEMs) related to 
the safety and efficacy of the use BTX injections for FOG episodes experienced by PD patients. 
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These outcomes were measured using United Parkinson’s Disease Rating Scale (UPDRS). The 
UPDRS uses patient questionnaire as well as clinical observation to assess the activities of daily 
living and motor abilities of PD patients.  
RESULTS: 
 Three studies investigated the impact that BTX injections had on the FOG episodes 
experienced by patients who had been diagnosed with PD. All three studies were RCTs: the first 
study was a double blind, two-period cross over design,6 the second study was a double blind, 
placebo parallel design,7 and the third study was a double-blind placebo design.8 
 In Wieler et al., twelve participants were selected, three women and nine men. The 
sample of patients consisted of 53 to 79 year olds with PD, with the average patient being 77 
years old.6 Patients were selected based on adherence to inclusion and exclusion criteria listed in 
Table 1. The patients were randomly assigned to either a placebo saline injection group followed 
by a BTX injection group, or a BTX injection group followed by a placebo saline injection 
group.6 All participants were assessed at baseline and then received the first set of injections 4 
weeks later.6 At week 8, patients were evaluated for any changes in their condition. At week 16, 
the groups were switched and the next set of injections were given. At week 20, patients were 
again assessed for any changes from baseline. The BTX group received 200-300 units, which 
were injected into the medial and lateral heads of the gastrocnemius and into the soleus muscles 
for a total of 16.25-25 U/injection into six different injection sites.6 At the follow up visits, 
diaries, freezing of gait questionnaires, and UPDRS were used to assess basic mobility.6 A 
Parkinson’s disease questionnaire (PDQ39 mobility) was used to assess quality of life.6 
This study demonstrates that after BTX injections, there were no statistically significant 
differences from the baseline visit to the post-treatment visit that were captured by the FOG-Q 
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(p>0.18), UPDRS 14 (p>1.0), UPDRS 15 (p>1.0), PDQ39 mobility (p>0.95).6 The mean change 
from baseline was 0, representing absolutely no changes post-treatment. Table 2 is an 
independent T-test, which demonstrates the differences between the placebo and BTX groups. 
There were no evidence of adverse effects, however one subject did report leg weakness 
that lasted for one week post BTX injection that was described as “my legs felt like jelly for a 
couple of days.”6 While there was no evidence of improvement, participant’s comments alluded 
to possible improvements after injections.6 Another patient stated there was a decrease in 
nocturnal leg cramping after BTX injections for approximately 3 weeks.6 
Table 2: Mean difference at placebo baseline, placebo week 4, BTX baseline, and BTX week 4.6 
 Mean difference (SD) P value 
UPDRS 14 0 (SD= 0.26) 1.00 
UPDRS 15 0 (SD=0.55) 1.00 
 
In the Fernandez et al. study, fourteen participants were selected.7 The patient’s ages 
ranged from 61 to 87 years old, with the mean age being 74.7 Participants had an average 
duration of PD for ten years.7 Patients were selected based on having idiopathic PD and FOG 
refractory to medical treatment as well as if they met inclusion criteria listed in Table 1.7 Of the 
fourteen participants, nine were randomly selected to receive intramuscular BTX injections and 
five were chosen to receive placebo.7 This group received 5000 U of BTX-B injections into four 
areas of the soleus and gastrocnemius muscle of the predominantly affected leg.7 If both legs 
seemed to be affected equally, then the side on which the disease process began was selected.7 
This study did not show any statistically significant changes between the placebo and treatment 
group at baseline and at 1 month post treatment (p>0.15).7 There was also no statistically 
significant changes before and after treatment within the group of patients receiving BTX 
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injections based on the UPDRS (p>0.80).7 The mean change from baseline was -0.6, which 
proves that this intervention did not have an impact on the patients.7 Table 3 illustrates the scores 
between the BTX and control groups. 
 The BTX injections were tolerated well by all patients in this study. The only adverse 
effects that were reported were dry mouth, experienced by two patients, and festination, which is 
an involuntary quickening of gait, reported by one patient.7 
Table 3: UPDRS mean scores at baseline, and one month.7 
UPDRS Score Baseline score 1 month P value (1 
month) 
BTX group 18.7 18.1 0.8 
Control group 17.8 17.4 0.8 
 
 In the Gurevich et al. study, eleven participants were selected, three females and eight 
males.8 The patient’s ages ranged from 56 to 86 years old with the mean age being 69.4 years 
old.8 Patients were selected based on the inclusion and exclusion criteria listed in Table 1. Six 
patients were randomly selected to receive BTX injections and five patients were assigned to 
receive saline injections.8 Baseline assessments were done at four and two weeks before as well 
as on the day of injection.8 The participants received 150 IU of BTX injections, 50 IU into the 
medial and lateral heads of the gastrocnemius as well as 50 IU into the soleus, of each leg for a 
total of 300 IU of BTX per participant.8 Post-injection, patients were evaluated at 2, 4, 8, 12, 16, 
and 20 weeks during which activities of daily living were assessed using UDPRS.8 
 There were insignificant changes found from baseline based on the UPDRS motor scale 
(p<0.10).8 Mean change from baseline was measured to be +2.0, which is small given the type 
and size of the population.8 Table 4 demonstrates the changes between the placebo and BTX 
groups.  
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People participating in this study experienced numerous adverse effects. Of the six 
patients receiving BTX injections, three patients reported leg weakness, as did two patients who 
were receiving the placebo, however the leg weakness was not demonstrated by the clinical 
assessment.8 Participants in both treatment and placebo group in the two to four weeks post 
injection reported pain.8 One patient receiving BTX injections was diagnosed with xerotic 
dermatitis in the six weeks following injection that lasted throughout the rest of the study.8 
Another adverse affect was an increase in number of reported falls. This seemed to improve by 
the end of the 20th week study, but overall, falls did increase significantly in the BTX group.8  
Table 4: UPDRS mean change at baseline, 4 weeks, and 20 weeks.8 
UPDRS motor Baseline 4 weeks 20 weeks P value 
BTX injections 33.0 (+10.7) 38.2 (+15.2) 43.8 (+8.3) P<0.10 
Control group 35.6 (+11.8) 34.0 (+14.7) 32.0 (+8.0) Insignificant 
 
DISCUSSION: 
 Parkinson’s disease is an extremely debilitating disease with no imminent cure. Freezing 
of gait is a common complaint that leads to an increase in number of falls leading to a greater 
number of injuries and hospitalizations.4 While treatments are available that can treat symptoms 
of PD as well as slow the progression, nothing has proven to completely treat and resolve the 
associated problems of PD.2 BTX injections did not prove to be a promising addition to the 
treatment options for PD.  
 The three RCT’s evaluated by this systematic review showed that the use of BTX 
injections for the FOG experienced by PD patients does not prove to be affective in improving 
motor abilities or activities of daily living.  
 BTX acts by binding to sites on cholinergic pre-synaptic nerve terminals and decreases 
the release of acetylcholine.5 In doing this, it acts as a neuromuscular blocker.5 Therefore, BTX, 
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while most popular for it’s cosmetic usages, can be therapeutic for a wide variety of conditions 
including dystonias, spasticity, strabismus, and chronic pain issues.5 However, when BTX is 
used in the wrong dose, dilution, or having been improperly stored, has been shown to have 
adverse effects.5 Adverse reaction to BTX is more likely to be seen when being used as a therapy 
rather than for cosmetic usage.5 A few commonly reported side effects include respiratory 
problems, dysphagia, seizures, flulike syndrome, weakness, ptosis, or reaction at site of 
injection.5 
There are a few limitations in the RCTs used. Each study was quite small, which may 
have precluded any ability to detect a significant benefit. A larger group may reveal benefits of 
BTX injections that was unable to be seen here. Also, there is no known dose of BTX that has 
been shown to be effective. Because of this, it is unknown if higher doses would have 
contributed to more significant symptom reduction. Muscle selection is another limitation of 
these studies as only the gastrocnemius-soleus complex was injected. In the future, other muscle 
targets could be evaluated, for example, the muscles in the anterior compartment of the leg.  
CONCLUSION: 
 BTX is used to treat a wide variety of disease and neurological symptoms ranging from 
focal dystonias of the face or limbs to migraine headaches. Its use in the treatment of PD is still 
nebulous. None of the studies evaluated in this review demonstrated a significant benefit of BTX 
on the FOG episodes experienced by PD patients. Since no extreme adverse drug reactions were 
shown to be an issue with this treatment, it may be beneficial to proceed with more studies in 
order to further evaluate it’s safety and efficacy. Future studies should include a larger number of 
subjects. The reviewed studies do not show extreme promise in any major developments in the 
treatment for PD. 
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